Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor-2 (HER2/ErbB-2), has become the mainstay of treatment for HER2-positive breast cancer. Nevertheless, its exact mechanism of action has not been fully elucidated. Although several studies suggest that Fc receptor-expressing immune cells are involved in trastuzumab therapy, the relative contribution of lymphocyte-mediated cellular cytotoxicity and antitumor cytokines remains unknown. We report here that anti-ErbB-2 mAb therapy is dependent on the release of type I and type II IFNs but is independent of perforin or FasL. Our study thus challenges the notion that classical antibody-dependent, lymphocyte-mediated cellular cytotoxicity is important for trastuzumab. We demonstrate that anti-ErbB-2 mAb therapy of experimental tumors derived from MMTV-ErbB-2 transgenic mice triggers MyD88-dependent signaling and primes IFN-γ-producing CD8+ T cells. Adoptive cell transfer of purified T cell subsets confirmed the essential role of IFN-γ-producing CD8+ T cells. Notably, anti-ErbB-2 mAb therapy was independent of IL-1R or IL-17Ra signaling. Finally, we investigated whether immunostimulatory approaches with antibodies against programmed death-1 (PD-1) or 41BB (CD137) could be used to capitalize on the immune-mediated effects of trastuzumab. We demonstrate that anti-PD-1 or anti-CD137 mAb can significantly improve the therapeutic activity of anti-ErbB-2 mAb in immunocompetent mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In this case, anti-PD1 would inhibit IFNγ-activated T cells and anti-CD37 would block CD8+ T cells; both of these T-cell subtypes are required for the adaptive immune response triggered by trastuzumab (Stagg et al., 2011).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Stagg et al., 2011
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredIn the citing paper
“tation on MHC class I and II molecules (Kono et al., 2004; Triulzi et al., 2018), as well as MYD88 innate immune signal transduction adaptor (MYD88)-dependent immunostimulation (Stagg et al., 2011), culminating in increased antigen processing and presentation by DCs (Gall et al., 2017).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Stagg et al., 2011
In the citing paper
“This applies to the humanized HER2-specific mAbs trastuzumab and pertuzumab (Misumi et al., 2018; Park et al., 2010; Stagg et al., 2011).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Stagg et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 1×
“The importance of FcR+ immune cells for trastuzumab therapy is supported by the fact that anti-HER2 antibodies incapable of binding FcR are ineffective against tumor xenografts (4), whereas antibodies with increased FcR binding show greater activity (9).”
BackgroundTrastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Self-citationAdaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,436
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981 · cited 1×
“Finally, for some patients, specific Fcr genotypes are associated with improved progression-free survival in response to trastuzumab (5).”
BackgroundTakeda, K., Hayakawa, Y., Smyth, M. J., Kayagaki, N., Yamaguchi, N., Kakuta, S., Iwakura, Y., Yagita, H., & Okumura, K. (2001) · Nature Medicine · doi:10.1038/83416 · Cited by 775
Berger, R., Rotem-Yehudar, R., Slama, G., Landes, S., Kneller, A., Leiba, M., Koren-Michowitz, M., Shimoni, A., & Nagler, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4079 · Cited by 680
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity
Park, S., Jiang, Z., Mortenson, E. D., Deng, L., Radkevich-Brown, O., Yang, X., Sattar, H., Wang, Y., Brown, N. K., Greene, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.014 · Cited by 577 · cited 4×
“It is further supported by the fact that FcR-deficient mice fail to respond to anti–ErbB-2 mAb therapy (10).”
BackgroundResultInfluentialUntch, M., Rezai, M., Loibl, S., Fasching, P. A., Huober, J., Tesch, H., Bauerfeind, I., Hilfrich, J., Eidtmann, H., Gerber, B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8451 · Cited by 556
Cited by
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182
“…nonIR m g30 40 50 ** *** IR nonIR 0m g 0 500 WT Tmem173-/- pg /m 0 10 20 WT Tmem173-/- pg /1 0 C 15 WT IR* ** 10 -non WT-IR Tmem173-/--nonIR Tmem173-/--IR -β m RN A at iv e x1 0- 7 ) - D4 5 +1c - 11 c 0 5Ifn - (r el a C CD 1 CD+ CD 11 b (Apetoh et al., 2007; Park et al., 2010; Stagg et al., 2011).”
Loi, S., Sirtaine, N., Piette, F., Salgado, R., Viale, G., Van Eenoo, F., Rouas, G., Francis, P., Crown, J. P. A., Hitre, E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0902 · Cited by 1,632
Combining immunotherapy and targeted therapies in cancer treatment
Vanneman, M., & Dranoff, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3237 · Cited by 1,586
“In experimental models, the combination of HER2 antibodies with either blocking PD1 antibodies or agonistic 4-1BB antibodies accomplished greater tumour growth control than either monotherap”
Background
Metadata
- Authors
- Stagg, J., Loi, S., Divisekera, U., Ngiow, S. F., Duret, H., Yagita, H., Teng, M. W., & Smyth, M. J.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- Institut Jules Bordet (BE)
- The University of Melbourne (AU)
- Department of Immunology, Juntendo University School of Medicine, Tokyo 113-8421, Japan
- Corresponding author
- Smyth, Mark J.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2011-04-11
- Volume
- 108
- Issue
- 17
- Pages
- 7142-7147
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3084100
- OpenAlex
- W2066471812
- Cited by
- 496
- References
- 34
- Citations by year
- 2026: 15 · 2025: 24 · 2024: 29 · 2023: 36 · 2022: 33 · 2021: 43 · 2020: 22 · 2019: 45 · 2018: 39 · 2017: 37 · 2016: 45 · 2015: 40 · 2014: 32 · 2013: 27 · 2012: 19
- FWCI
- 13.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Funders
- Medical Research Council
- National Health and Medical Research Council
- Japan Society for the Promotion of Science (22240089)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- trastuzumab, HER2-positive breast cancer, type I interferon, interferon-gamma, MyD88 signaling, antibody-dependent cellular cytotoxicity, Fc receptors, adoptive T cell therapy, anti-PD-1 therapy, immune checkpoint blockade, combination immunotherapy
- MeSH terms
- Trastuzumab, Animals, Antibodies, Monoclonal, Antigens, Surface, Antineoplastic Combined Chemotherapy Protocols, Humans, Interferon Type I, Interferon-gamma, Mice, Inbred BALB C, Mice, Transgenic, Mammary Neoplasms, Animal, Mice, SCID, CD8-Positive T-Lymphocytes, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Adoptive Transfer, Cell Line, Tumor, Apoptosis Regulatory Proteins, Mice, Tumor Necrosis Factor Receptor Superfamily, Member 9, Receptors, Interleukin-1 Type I, Receptors, Interleukin-17, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. https://app.cochat.ai/papers/10.1073/pnas.1016569108
- The paper
- Stagg, J., Loi, S., Divisekera, U., Ngiow, S. F., Duret, H., Yagita, H., Teng, M. W., & Smyth, M. J. (2011). Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1016569108
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.